About Kindred Biosciences (NASDAQ:KIN)
Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company's lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company's other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.
Industry, Sector and Symbol:
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Sector: Medical
- Symbol: NASDAQ:KIN
- CUSIP: N/A
- Web: www.kindredbio.com
- Current Ratio: 24.02%
- Quick Ratio: 24.02%
Sales & Book Value:
- Annual Sales: N/A
- Price / Sales: N/A
- Book Value: $2.90 per share
- Price / Book: 2.53
- Trailing EPS: ($1.17)
- Net Income: ($22,490,000.00)
- Return on Equity: -36.18%
- Return on Assets: -34.66%
- Employees: 41
- Outstanding Shares: 28,160,000
Frequently Asked Questions for Kindred Biosciences (NASDAQ:KIN)
What is Kindred Biosciences' stock symbol?
Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."
How were Kindred Biosciences' earnings last quarter?
Kindred Biosciences, Inc. (NASDAQ:KIN) released its quarterly earnings data on Tuesday, November, 7th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.04. View Kindred Biosciences' Earnings History.
Where is Kindred Biosciences' stock going? Where will Kindred Biosciences' stock price be in 2017?
5 Wall Street analysts have issued 12-month price targets for Kindred Biosciences' shares. Their predictions range from $8.00 to $10.50. On average, they anticipate Kindred Biosciences' share price to reach $9.50 in the next year. View Analyst Ratings for Kindred Biosciences.
Who are some of Kindred Biosciences' key competitors?
Some companies that are related to Kindred Biosciences include Insys Therapeutics (INSY), Progenics Pharmaceuticals (PGNX), NantKwest (NK), Corbus Pharmaceuticals Holdings (CRBP), MannKind Corporation (MNKD), Seres Therapeutics (MCRB), CymaBay Therapeutics (CBAY), AVEO Pharmaceuticals (AVEO), Mersana Therapeutics (MRSN), Calithera Biosciences (CALA), NuCana PLC Sponsored ADR (NCNA), Stemline Therapeutics (STML), Mast Therapeutics (SVRA), ObsEva SA (OBSV), Bellicum Pharmaceuticals (BLCM), Biotie Therapies Corp (BITI), Ra Pharmctl (RARX) and BioTime (BTX).
Who are Kindred Biosciences' key executives?
Kindred Biosciences' management team includes the folowing people:
- Wendy Wee, Chief Financial Officer (Age 64)
- Denise M. Bevers, Chief Operating Officer, Secretary (Age 47)
- Stephen Sundlof Ph.D., Executive Vice President - Regulatory Affairs and Quality, Chief Scientific Officer (Age 63)
- Herbert D. Montgomery, Independent Director (Age 68)
- Raymond Townsend, Independent Director (Age 70)
- Ervin Veszpremi, Independent Director (Age 56)
Who owns Kindred Biosciences stock?
Kindred Biosciences' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Dimensional Fund Advisors LP (4.82%), General American Investors Co. Inc. (2.39%), Wells Fargo & Company MN (1.20%), New York State Common Retirement Fund (0.95%), Pacific Grove Capital LP (0.67%) and Granite Investment Partners LLC (0.33%). Company insiders that own Kindred Biosciences stock include Ernest Mario, Park West Asset Management Llc, Raymond Townsend and Richard Chin. View Institutional Ownership Trends for Kindred Biosciences.
Who sold Kindred Biosciences stock? Who is selling Kindred Biosciences stock?
Kindred Biosciences' stock was sold by a variety of institutional investors in the last quarter, including Granite Investment Partners LLC and Dimensional Fund Advisors LP. Company insiders that have sold Kindred Biosciences company stock in the last year include Park West Asset Management Llc and Richard Chin. View Insider Buying and Selling for Kindred Biosciences.
Who bought Kindred Biosciences stock? Who is buying Kindred Biosciences stock?
Kindred Biosciences' stock was purchased by a variety of institutional investors in the last quarter, including General American Investors Co. Inc., Pacific Grove Capital LP, New York State Common Retirement Fund, Granahan Investment Management Inc. MA, SG Americas Securities LLC, Trexquant Investment LP, Bank of New York Mellon Corp and Prudential Financial Inc.. Company insiders that have bought Kindred Biosciences stock in the last two years include Ernest Mario, Park West Asset Management Llc and Raymond Townsend. View Insider Buying and Selling for Kindred Biosciences.
How do I buy Kindred Biosciences stock?
Shares of Kindred Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kindred Biosciences' stock price today?
One share of Kindred Biosciences stock can currently be purchased for approximately $7.35.
How big of a company is Kindred Biosciences?
Kindred Biosciences has a market capitalization of $206.96 million. The biopharmaceutical company earns ($22,490,000.00) in net income (profit) each year or ($1.17) on an earnings per share basis. Kindred Biosciences employs 41 workers across the globe.
How can I contact Kindred Biosciences?
Kindred Biosciences' mailing address is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. The biopharmaceutical company can be reached via phone at 650-701-7901 or via email at [email protected]
MarketBeat Community Rating for Kindred Biosciences (NASDAQ KIN)MarketBeat's community ratings are surveys of what our community members think about Kindred Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Kindred Biosciences (NASDAQ:KIN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 1 Hold Rating, 3 Buy Ratings, 1 Strong Buy Rating|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$9.50 (29.25% upside)|
Consensus Price Target History for Kindred Biosciences (NASDAQ:KIN)
Analysts' Ratings History for Kindred Biosciences (NASDAQ:KIN)
(Data available from 11/20/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|11/17/2017||HC Wainwright||Initiated Coverage||Buy -> Buy||$9.50||N/A|
|5/31/2017||FBR & Co||Reiterated Rating||Buy||Low|
|5/15/2017||BMO Capital Markets||Reiterated Rating||Hold||$8.00||N/A|
|1/3/2017||Feltl & Co.||Reiterated Rating||Strong-Buy||N/A|
|11/1/2016||Ladenburg Thalmann Financial Services||Initiated Coverage||Buy||$7.50||N/A|
Earnings History and Estimates Chart for Kindred Biosciences (NASDAQ:KIN)
Earnings History by Quarter for Kindred Biosciences (NASDAQ KIN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Kindred Biosciences (NASDAQ:KIN)
Current Year EPS Consensus Estimate: $-1.14 EPS
Next Year EPS Consensus Estimate: $-1.09 EPS
Dividend History for Kindred Biosciences (NASDAQ:KIN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Kindred Biosciences (NASDAQ KIN)
Insider Ownership Percentage: 19.10%
Institutional Ownership Percentage: 61.77%
Insider Trades by Quarter for Kindred Biosciences (NASDAQ KIN)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|7/12/2017||Park West Asset Management Llc||Major Shareholder||Buy||600,000||$7.50||$4,500,000.00|| |
|7/3/2017||Richard Chin||Insider||Sell||13,000||$8.26||$107,380.00|| |
|6/22/2017||Richard Chin||Insider||Sell||13,000||$7.75||$100,750.00|| |
|6/8/2017||Park West Asset Management Llc||Major Shareholder||Buy||15,311||$6.65||$101,818.15|| |
|5/11/2017||Park West Asset Management Llc||Major Shareholder||Buy||155,076||$6.83||$1,059,169.08|| |
|3/15/2017||Park West Asset Management Llc||Major Shareholder||Buy||400,000||$6.60||$2,640,000.00|| |
|3/13/2017||Park West Asset Management Llc||Major Shareholder||Buy||4,200||$6.20||$26,040.00|| |
|3/9/2017||Park West Asset Management Llc||Major Shareholder||Buy||18,066||$6.08||$109,841.28|| |
|1/13/2017||Park West Asset Management Llc||Major Shareholder||Buy||1,690,000||$6.20||$10,478,000.00|| |
|1/9/2017||Park West Asset Management Llc||Major Shareholder||Buy||131,500||$5.30||$696,950.00|| |
|1/6/2017||Park West Asset Management Llc||Major Shareholder||Buy||110,617||$5.10||$564,146.70|| |
|12/16/2016||Park West Asset Management Llc||Insider||Sell||18,000||$4.78||$86,040.00|| |
|12/14/2016||Park West Asset Management Llc||Major Shareholder||Buy||8,334||$4.75||$39,586.50|| |
|12/13/2016||Park West Asset Management Llc||Major Shareholder||Buy||1,148||$4.75||$5,453.00|| |
|12/12/2016||Park West Asset Management Llc||Major Shareholder||Buy||3,112||$4.74||$14,750.88|| |
|3/15/2016||Ernest Mario||Director||Buy||30,000||$3.55||$106,500.00|| |
|11/23/2015||Raymond Townsend||Director||Buy||2,000||$4.00||$8,000.00|| |
|11/18/2015||Raymond Townsend||Director||Buy||2,323||$4.78||$11,103.94|| |
|8/31/2015||Raymond Townsend||Director||Buy||1,677||$5.85||$9,810.45|| |
|8/14/2015||Raymond Townsend||Director||Buy||3,000||$6.04||$18,120.00|| |
|9/29/2014||Oleg Nodelman||Director||Buy||100,000||$9.56||$956,000.00|| |
|9/3/2014||Ernest Mario||Director||Buy||10,000||$10.55||$105,500.00|| |
|8/28/2014||Oleg Nodelman||Director||Buy||47,000||$10.85||$509,950.00|| |
|8/26/2014||Oleg Nodelman||Director||Buy||85,244||$10.50||$895,062.00|| |
|12/12/2013||Kevin Schultz||Insider||Buy||4,000||$7.00||$28,000.00|| |
|12/12/2013||Oleg Nodelman||Director||Buy||400,000||$7.00||$2,800,000.00|| |
|12/12/2013||Stephen Sundlof||SVP||Buy||1,000||$7.00||$7,000.00|| |
Latest Headlines for Kindred Biosciences (NASDAQ KIN)
|Kindred Biosciences, Inc. (KIN) Coverage Initiated by Analysts at HC Wainwright|
www.americanbankingnews.com - November 18 at 11:38 AM
|Kindred Biosciences, Inc. (KIN) Given Consensus Rating of "Buy" by Analysts|
www.americanbankingnews.com - November 16 at 7:50 PM
|Edited Transcript of KIN earnings conference call or presentation 7-Nov-17 9:30pm GMT|
finance.yahoo.com - November 13 at 11:02 AM
|Kindred Biosciences, Inc. (KIN) Issues Quarterly Earnings Results|
www.americanbankingnews.com - November 8 at 7:11 PM
|Kindred Biosciences Announces Third Quarter 2017 Financial Results|
www.bizjournals.com - November 8 at 11:27 AM
|Kindred Biosciences, Inc. (KIN) Expected to Announce Earnings of -$0.33 Per Share|
www.americanbankingnews.com - November 4 at 5:24 PM
|Kindred Biosciences, Inc. (KIN) Set to Announce Earnings on Tuesday|
www.americanbankingnews.com - October 31 at 11:58 AM
|Kindred Biosciences, Inc. (KIN) Receives Consensus Recommendation of "Buy" from Brokerages|
www.americanbankingnews.com - October 22 at 8:38 PM
|Kindred Biosciences to Announce Third Quarter 2017 Financial Results|
finance.yahoo.com - October 11 at 5:05 PM
|Contrasting Kindred Biosciences (KIN) & Pain Therapeutics (PTIE)|
www.americanbankingnews.com - October 6 at 4:10 PM
|Kindred Biosciences to Participate in the Oppenheimer & Co. Specialty Pharmaceuticals Conference|
finance.yahoo.com - October 6 at 2:37 AM
|Head-To-Head Analysis: Spark Therapeutics (ONCE) & Kindred Biosciences (KIN)|
www.americanbankingnews.com - October 1 at 2:32 AM
|Kindred Biosciences, Inc. (KIN) Receives Consensus Recommendation of "Buy" from Analysts|
www.americanbankingnews.com - September 27 at 8:44 PM
|Kindred Biosciences (KIN) Presents At Ladenburg Thalmann 2017 Healthcare Conference - Slideshow|
seekingalpha.com - September 27 at 4:17 PM
|Comparing Kindred Biosciences (KIN) and Its Peers|
www.americanbankingnews.com - September 20 at 8:08 AM
|Kindred Biosciences Announces Plans for Promotion of Dr. Zhan and Retirement of Dr. Sundlof|
finance.yahoo.com - September 11 at 9:35 PM
|Kindred Biosciences, Inc. (KIN) Given Average Rating of "Buy" by Analysts|
www.americanbankingnews.com - September 2 at 8:46 PM
|Kindred Biosciences to Present at Upcoming Investor Conferences|
finance.yahoo.com - August 31 at 6:40 AM
|Kindred Biosciences, Inc. (KIN) Short Interest Down 29.0% in July|
www.americanbankingnews.com - August 14 at 3:04 AM
|Kindred Biosciences, Inc. (NASDAQ:KIN) Releases Quarterly Earnings Results|
www.americanbankingnews.com - August 8 at 11:14 AM
|Edited Transcript of KIN earnings conference call or presentation 7-Aug-17 8:30pm GMT|
finance.yahoo.com - August 8 at 5:40 AM
|Kindred Biosciences Announces Second Quarter 2017 Financial Results|
finance.yahoo.com - August 7 at 7:38 PM
|Kindred Biosciences Sponsors Veterinary Students to Attend the 2017 American Association of Feline Practitioners Meeting|
finance.yahoo.com - August 4 at 11:59 PM
| Brokerages Anticipate Kindred Biosciences, Inc. (KIN) Will Post Earnings of -$0.29 Per Share|
www.americanbankingnews.com - August 2 at 10:14 PM
|Kindred Biosciences, Inc. (KIN) Short Interest Update|
www.americanbankingnews.com - July 29 at 7:15 AM
|BRIEF-Kindred Biosciences says board appointed Wendy Wee as CFO - SEC Filing|
www.reuters.com - July 29 at 1:09 AM
|Kindred Biosciences to Announce Second Quarter 2017 Financial Results|
finance.yahoo.com - July 24 at 10:19 AM
|Kindred Biosciences, Inc. (NASDAQ:KIN) Receives Average Rating of "Buy" from Brokerages|
www.americanbankingnews.com - July 14 at 10:52 PM
|Park West Asset Management Llc Purchases 600,000 Shares of Kindred Biosciences, Inc. (KIN) Stock|
www.americanbankingnews.com - July 14 at 7:59 PM
|KindredBio Announces Pricing of Public Offering|
finance.yahoo.com - July 13 at 6:07 AM
|BRIEF-Kindredbio announces proposed public offering of common stock|
www.reuters.com - July 12 at 1:51 AM
|KindredBio Announces Proposed Public Offering of Common Stock|
finance.yahoo.com - July 12 at 1:51 AM
|Kindred Biosciences, Inc. (NASDAQ:KIN) Expected to Post Earnings of -$0.29 Per Share|
www.americanbankingnews.com - July 11 at 2:28 PM
|Former Boehringer Ingelheim manufacturing plant finds new owner|
www.bizjournals.com - July 7 at 6:46 AM
|Richard Chin Sells 13,000 Shares of Kindred Biosciences, Inc. (KIN) Stock|
www.americanbankingnews.com - July 6 at 8:06 PM
|Kindred Biosciences (KIN) Buys Kansas Manufacturing Plant and Reports Execution of Commercial Manufacturing Agreement for Zimeta|
www.streetinsider.com - June 26 at 8:03 PM
|BRIEF-Kindred Biosciences reports acquisition of Kansas manufacturing plant|
www.reuters.com - June 26 at 8:03 PM
|BRIEF-Kindred Biosciences announces Q1 loss per share $0.30|
www.reuters.com - May 4 at 1:16 AM
|Kindred Biosciences, Inc. 2017 Q1 - Results - Earnings Call Slides|
seekingalpha.com - May 4 at 1:16 AM
|Q4 2016 Kindred Biosciences Inc Earnings Release - After Market Close|
biz.yahoo.com - March 1 at 11:27 AM
|Kindred Biosciences (KIN) Receives Technical Section Complete Letter for Effectiveness from FDA for Mirataz New Animal Drug Application|
www.streetinsider.com - February 6 at 11:19 PM
|BRIEF-Kindred Biosciences receives early approval of effectiveness technical section from FDA for Mirataz|
www.reuters.com - February 6 at 6:17 PM
|9:00 am Kindred Biosciences receives early approval of effectiveness technical section from the FDA for Mirataz new animal drug application (shares halted)|
us.rd.yahoo.com - February 6 at 10:21 AM
|Kindred Biosciences (KIN) Looks Good: Stock Jumps 9.5%|
www.zacks.com - January 16 at 8:35 AM
|KindredBio: An Undervalued, Under-Followed, Low-Float Play On The Humanization Of Pets|
seekingalpha.com - January 14 at 12:26 AM
|KINDRED BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement|
biz.yahoo.com - December 20 at 11:45 AM
|KINDRED BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits|
biz.yahoo.com - December 7 at 6:14 PM
|BRIEF-Kindred Biosciences to present Zimeta pivotal data at Annual American Association of Equine Practitioners Convention|
www.reuters.com - November 29 at 4:18 PM
|Tracking Seth Klarman's Baupost Group Holdings - Q3 2016 Update|
seekingalpha.com - November 16 at 9:29 AM
|Kindred Biosciences Announces Third Quarter 2016 Financial Results|
www.prnewswire.com - November 7 at 9:38 AM
Kindred Biosciences (NASDAQ KIN) Chart for Monday, November, 20, 2017